

SUPPLEMENTARY DATA

**ATHOS (ATención Hospitalaria del Síndrome Coronario) Study
investigators and collaborators**

Coordinating Center – IMIM, Barcelona

Coordinator: Jaume Marrugat, Laboratory manager: Daniel Muñoz; Laboratory technicians: Gemma Blanchart, Sonia Gaixas; Data managers: Marta Cabañero, Leny Franco, Susanna Tello; Statical team: Isaac Subirana, Andrea Toloba

Board

Roberto Elosua, Francisco Fernández-Avilés, David García Dorado, Rosa M^a Lidón Corbi and Jaume Marrugat.

Participant hospitals	PIs & collaborating investigators	Other collaborators
Hospital Universitario Virgen Victoria	PI: Manuel Jiménez-Navarro, Oscar Lamas	Project manager: Alicia Guerrero
Hospital Clínic de Barcelona	PI: Mercè Roqué, Rut Andrea, Carlos Falces, Manel Sabaté	Nurse: Elisabet Codina, Elisabet de Mingo, Residents: Eduardo Flores, Luis Ortega, Paula Sánchez
Hospital Universitari Germans Trias i Pujol	PI: Antoni Bayés, Laura Astier, Carlos Labata, Teresa Oliveras, Ferran Rueda	
Hospital Universitario Gregorio Marañón	PI: Antonio Mayorga, María Losada, Héctor Bueno, Míriam Juárez, Iago Sousa	
Hospital Universitario San Juan de Alicante	PI: Vicente Bertomeu González, Vicente Bertomeu Martínez, Jesús Castillo, Alberto Cordero	
Hospital Clínico Univ. de Valencia	PI: Juan Sanchis, M ^a Luisa Blasco, Luis Mainar, Estefanía Montalvo, Julio Núñez	
Hospital Univ. Virgen de la Candelaria	PIs: Marcos Rodríguez, Alejandro Quijada Fumero	
Consorci Sanitari de Terrassa	PI: Antonio Sánchez, M ^a Dolores Martínez, Cristina Moure	Giuseppe de Bernardo, Cora Oliveros
Hospital Univ. Miguel Servet	PIs: Esther Sánchez and María Lasala, Isabel Caballero, Isabel Calvo, Georgina Fuertes, M ^a del Rosario Ortas, Alejandra Ruiz	
Hospital Univ. de Basurto	PI: Ane Elorriaga, José M ^a Aguirre, Abel Andrés, Jesús Roberto Sáez	
Complejo Hospitalario Univ. de Santiago	PI: Emad Abu-Assi, José Ramón González, Sergio Raposeiras	
Fundación Hospital de Alcorcón	PI: Alberto Núñez, Javier Botas, Roberto del Castillo, Lorenzo Hernando	

Participant hospitals	PIs & collaborating investigators	Other collaborators
Hospital Univ. Central de Asturias	PI: José Manuel García, Alberto Alperi, Rebeca Lorca, Iria Silva	
Hospital Univ. Donostia	PI: Pedro Morrondo, Maialen Ganzarain, Izarne Totorika	
Hospital Univ. Josep Trueta	PI: Daniel Bosch, Xavier Albert, Jaume Aboal, Pablo Loma	
Hospital Galdakao - Usansolo	PI: Iñaki Lekuona, Alazne Urkullu, Germán Zugazabeitia	
Hospital Univ. Son Espases	PI: Andrés Carrillo, Miquel Fiol, Alberto Rodríguez, Jaime Emilio Herrero	
Hospital Comarcal Don Benito-Villanueva	PI: Daniel Fernández-Bergés, Montserrat Corraliza, Manuel Durán, Juan Diego Jiménez, Pedro Mellado	
Hospital Comarcal de Blanes	PI: Alberto Zamora, Guillem Paluzie, Ariadna Sureda, Montserrat Vilaseca	
Hospital de Cabueñes	PI: Íñigo Lozano, Berta Vega, Diego León, Julio Rubio	
Hospital Clínico Univ. Lozano Blesa	PI: Javier Alameda, Jara Gayán, Ana Martínez, Guillermo Pinillos, Adrián Riaño, Juan Manuel Salvador	
Hospital Son Llàtzer	PI: Catalina Rubert, Catalina Forteza, Lorenzo Socias, María Romero	
Hospital General Univ. de Ciudad Real	PI: Luis Ruiz-Valdepeñas, Ramón Maseda, Natalia Pinilla, Jesús Piqueras	
Hospital de Mendaro	PI: Laura Quintas, Rubén García, Cristina Goena, Inmaculada Lluís	
Complejo Hospitalario de Toledo	PI: Luis Rodríguez, Eva García, Andrés Sánchez	
Hospital Univ. Araba	PI: Jessica Vaquero, Fernando Arós, Ángel Loma-Osorio, Anai Moreno	
Hospital Univ. La Fe	PI: Luis Martínez, Raquel López Vilella, Josep Melero, Ydelise Rodríguez	
Hospital Univ. Vall d'Hebrón	PI: José A. Barrabés, Laia Milà, María Terricabras	
Hospital Universitario de Salamanca	PI: Pedro L. Sánchez, Pedro I. Dorado, Clara Sánchez, Francisco Martín, Pedro Pabón, Aitor Urribarri	Laura Torres
Hospital de la Santa Creu i Sant Pau	PI: Alessandro Sionis, Juan Cinca, Montserrat Vila, Albert Durán	
Hospital del Mar	PI: Julio Martí Almor, Helena Tizón Marcos, Beatriz Vaquerizo	Nurses: Paula Cabero, Cristina Soler

Table 1 of the supplementary data. Baseline patient characteristics by 5-year all-cause mortality

	No event	Death of any cause	<i>P</i>
	n = 2203	n = 121	
<i>Type of ACS on admission</i>			
STEACS	2168 (98.4)	115 (95.0)	.006
Nonclassifiable	35 (1.59)	6 (4.96)	
<i>Age, y</i>	61.4 ± 12.8	76.5 ± 10.6)	< .001
<i>Female sex</i>	437 (19.8)	25 (20.7)	.819
<i>Smoking</i>	1542 (70.0)	71 (58.7)	.008
<i>Hypertension</i>	1109 (50.3)	88 (72.7)	< .001
<i>Diabetes mellitus</i>	509 (23.1)	52 (43.0)	< .001
<i>Previous MI</i>	239 (10.8)	30 (24.8)	< .001
<i>Previous angina</i>	232 (10.5)	17 (14.0)	.234
<i>Previous stroke</i>	70 (3.18)	12 (9.92)	< .001
<i>Peripheral artery disease</i>	88 (3.99)	14 (11.6)	< .001
<i>Previous PCI</i>	214 (9.71)	26 (21.5)	< .001
<i>Previous CABG</i>	32 (1.45)	8 (6.61)	< .001
<i>Chronic respiratory disease</i>	165 (7.49)	24 (19.8)	< .001
<i>Chronic kidney disease</i>	84 (3.81)	23 (19.0)	< .001
<i>Glomerular filtration rate</i>	88.5 ± 37.7	72.0 ± 31.2	< .001
<i>Glycemia</i>	150 ± 66.3	165 ± 77.8	.021
<i>APE/CS or Killip III-IV</i>	143 (6.49)	24 (19.8)	< .001
<i>Left ventricular ejection fraction < 30%</i>	330 (19.5)	34 (37.4)	< .001
<i>Antiplatelet therapy intensity</i>			
Single antiplatelet therapy	1954 (95.4)	95 (4.64)	.001
Dual antiplatelet therapy	249 (90.5)	26 (9.45)	

ACS, acute coronary syndrome; APE, acute pulmonary oedema; CABG, coronary artery bypass graft;

CS, cardiogenic shock STEACS, ST-elevation ACS; MI, myocardial infarction; PCI, percutaneous coronary intervention.

The data are presented as No. (%).

Table 2 of the supplementary data. Baseline patient characteristics by 5-year cardiovascular mortality

	No event	Cardiovascular death	P
	n = 2286	n = 38	
<i>Type of ACS on admission</i>			< .001
STEACS	2249 (98.4)	34 (89.5)	
Nonclassifiable	37 (1.62)	4 (10.5)	
<i>Age, y</i>	62.0 ± 13.0	75.0 ± 11.6	< .001
<i>Female sex</i>	453 (19.8)	9 (23.7)	.551
<i>Smoking</i>	1590 (69.6)	23 (60.5)	.210
<i>Hypertension</i>	1167 (51.0)	30 (78.9)	.001
<i>Diabetes mellitus</i>	544 (23.8)	17 (44.7)	.002
<i>Previous MI</i>	258 (11.3)	11 (28.9)	.001
<i>Previous angina</i>	244 (10.7)	5 (13.2)	.626
<i>Previous stroke</i>	78 (3.41)	4 (10.5)	.011
<i>Peripheral artery disease</i>	97 (4.24)	5 (13.2)	.005
<i>Previous PCI</i>	230 (10.1)	10 (26.3)	.001
<i>Previous CABG</i>	37 (1.62)	3 (7.89)	.002
<i>Chronic respiratory disease</i>	178 (7.79)	11 (28.9)	< .001
<i>Chronic kidney disease</i>	101 (4.42)	6 (15.8)	< .001
<i>Glomerular filtration rate</i>	88.0 ± 37.7	69.0 ± 29.4	< .001
<i>Glycemia</i>	150 ± 66.8	168 ± 78.0	.112
<i>APE/CS or Killip III-IV</i>	159 (6.96)	8 (21.1)	< .001
<i>Left ventricular ejection fraction < 30%</i>	352 (20.1)	12 (38.7)	.008
<i>Antiplatelet therapy intensity</i>			
Single antiplatelet therapy	2021 (98.6)	28 (1.37)	.010
Dual antiplatelet therapy	265 (96.4)	10 (3.64)	

ACS, acute coronary syndrome; APE, acute pulmonary oedema; CABG, coronary artery bypass graft;

CS, cardiogenic shock STEACS, ST-elevation ACS; MI, myocardial infarction; PCI, percutaneous coronary intervention.

The data are presented as No. (%) or mean ± standard deviation.

Table 3 of the supplementary data. Baseline patient characteristics by 5-year cardiovascular readmission or mortality

	No event	Cardiovascular readmission/mortality	P
	n = 1614	n = 269	
Type of ACS on admission:			
STEACS	1591 (98.6%)	262 (97.4%)	.136
Nonclassifiable	23 (1.43%)	7 (2.60%)	
Age, y	61.3 ± 13.0	63.9 ± 13.6	.001
Female sex	308 (19.1)	55 (20.4)	.791
Smoking	1144 (70.9)	175 (65.1)	.055
Arterial hypertension:	787 (48.8)	167 (62.1)	< .001
Diabetes mellitus	340 (21.1)	91 (33.8)	< .001
Previous MI	149 (9.23)	58 (21.6)	< .001
Previous angina	130 (8.05)	51 (19.0)	< .001
Previous stroke	41 (2.54)	14 (5.20)	.009
Peripheral artery disease	58 (3.59)	17 (6.32)	.017
Previous PCI	125 (7.74)	53 (19.7)	< .001
Previous CABG	15 (0.93)	13 (4.83)	< .001
Chronic respiratory disease	112 (6.94)	27 (10.0)	.051
Chronic kidney disease	66 (4.09)	19 (7.06)	.004
Glomerular filtration rate	89.0 ± 32.4	82.6 ± 28.0	.001
Glycemia	147 ± 61.7	157 ± 73.3	.027
APE/CS or Killip III-IV	81 (5.02)	30 (11.2)	< .001
Left ventricular ejection fraction < 30%	216 (17.6)	57 (29.1)	< .001
Antiplatelet therapy intensity			
Single antiplatelet therapy	1531 (88.6)	197 (11.4)	< .001
Dual antiplatelet therapy	83 (53.5)	72 (46.5)	

ACS, acute coronary syndrome; APE, acute pulmonary oedema; CABG, coronary artery bypass graft;

CS, cardiogenic shock STEACS, ST-elevation ACS; MI, myocardial infarction; PCI, percutaneous coronary intervention.

The data are presented as No. (%) or mean ± standard deviation.

Table 4 of the supplementary data. Hazard ratio (HR) and 95% confidence interval (95%CI) of overall mortality, cardiovascular mortality, and cardiovascular readmission or mortality for dual compared with single antiplatelet therapy from 1 to 5 years after admission for an ST-elevation myocardial infarction adjusted by age and sex after 1:3 propensity matching¹

	HR (95%CI) 2.5% to 97.5%	Matching DAPT:SAPT
Overall mortality	1.59 (0.93-2.73)	273 : 806
Cardiovascular mortality	2.32 (0.96-5.62)	273 : 806
Cardiovascular readmission or mortality	4.87 (3.11-7.62)	154 : 446

Table 5 of the supplementary data. Hazard ratio (HR) and 95% confidence interval (95%CI) of overall mortality, cardiovascular mortality, and cardiovascular readmission or mortality for dual compared with single antiplatelet therapy from 1 to 5 years after admission for an ST-elevation myocardial infarction adjusted by age and sex by inverse propensity weighting²

	HR (95%CI) 2.5% to 97.5%
Overall mortality	1.77 (1.09-2.88)
Cardiovascular mortality	2.13 (0.97-4.71)
Cardiovascular readmission or mortality	4.77 (3.50-6.49)

Table 6 of the supplementary data. Baseline patient characteristics by participation

	Nonparticipants	Participants	P
	n = 744	n = 3591	
Type of ACS on admission			.188
STEACS	723 (97.2)	3520 (98.0)	
Nonclassifiable	21 (2.82)	71 (1.98)	
Age, y	64.7 ± 14.1	63.5 ± 13.6	.037
Female sex	158 (21.2)	753 (21.0)	.910
Smoking	498 (66.9)	2397 (66.8)	.956
Arterial hypertension	379 (50.9)	1881 (52.4)	.499
Diabetes mellitus	170 (22.8)	896 (25.0)	.244
Previous myocardial infarction	92 (12.4)	425 (11.8)	.731
Previous angina	76 (10.2)	341 (9.50)	.591
Previous stroke	38 (5.11)	152 (4.23)	.336
Peripheral artery disease	43 (5.78)	178 (4.96)	.403
Previous PCI	84 (11.3)	366 (10.2)	.408
Previous CABG	5 (0.67)	57 (1.59)	.081
Chronic respiratory disease	86 (11.6)	315 (8.77)	.020
Chronic kidney disease	44 (5.91)	193 (5.37)	.617
Glomerular filtration rate	84.4 ± 28.7	86.1 ± 40.6	.171
Glycemia	151 ± 69.	153 ± 71.3	.394
APE/CS or Killip III-IV	74 (9.95)	305 (8.49)	.228
Left ventricular ejection fraction < 30%	182 (27.0)	602 (21.9)	.006
Major bleeding	11 (1.48)	48 (1.34)	.897
Stroke during admission	5 (0.67)	26 (0.72)	1.000

ACS, acute coronary syndrome; APE, acute pulmonary oedema; CABG, coronary artery bypass graft;

CS, cardiogenic shock STEACS, ST-elevation ACS; MI, myocardial infarction; PCI, percutaneous coronary intervention.

The data are presented as No. (%) or mean ± standard deviation.

Table 7 of the supplementary data. Baseline patient characteristics by follow-up status

	Lost to follow-up	Followed-up	<i>P</i>
	n = 484	n = 3107	
<i>Type of ACS on admission</i>			.075
STEACS	480 (99.2)	3040 (97.8)	
Nonclassifiable	4 (0.83)	67 (2.16)	
<i>Age, y</i>	63.9 ± 14.2	63.4 ± 13.6	.467
<i>Female sex</i>	117 (24.2)	636 (20.5)	.072
<i>Smoking</i>	306 (63.2)	2091 (67.3)	.086
<i>Hypertension</i>	241 (49.8)	1640 (52.8)	.239
<i>Diabetes mellitus</i>	116 (24.0)	780 (25.1)	.630
<i>Previous MI</i>	39 (8.06)	386 (12.4)	.007
<i>Previous angina</i>	28 (5.79)	313 (10.1)	.004
<i>Previous stroke</i>	17 (3.51)	135 (4.35)	.468
<i>Peripheral artery disease</i>	28 (5.79)	150 (4.83)	.430
<i>Previous PCI</i>	40 (8.26)	326 (10.5)	.154
<i>Previous CABG</i>	5 (1.03)	52 (1.67)	.393
<i>Chronic respiratory disease</i>	41 (8.47)	274 (8.82)	.869
<i>Chronic kidney disease</i>	19 (3.93)	174 (5.60)	.158
<i>Glomerular filtration rate</i>	88.1 ± 58.8	85.8 ± 36.9	.405
<i>Glycemia</i>	154 ± 70.6	153 ± 71.4	.895
<i>APE/CS or Killip III-IV</i>	43 (8.88)	262 (8.43)	.807
<i>Left ventricular ejection fraction < 30%</i>	91 (22.3)	511 (21.9)	.895
<i>Major bleeding</i>	9 (1.86)	39 (1.26)	.388
<i>Stroke during admission</i>	4 (0.83)	22 (0.71)	1.000

ACS, acute coronary syndrome; APE, acute pulmonary edema; CABG, coronary artery bypass graft; CS, cardiogenic shock STEACS, ST-elevation ACS; MI, myocardial infarction; PCI, percutaneous coronary intervention.

The data are presented as No. (%) or mean ± standard deviation.

REFERENCES

1. Ho DE, Imai K, King G, Stuart EA. MatchIt: Nonparametric Preprocessing for Parametric Causal Inference. *J Statistical Software*. 2011;42:1-28.
2. Austin PC. Variance estimation when using inverse probability of treatment weighting (IPTW) with survival analysis. *Stat Med*. 2016;35:5642-5655